Microaxial pump cannula
VA-ECMO, IABP, and pVAD cannulas (8–21 Fr) occupy the common femoral artery, mechanically blocking flow to the leg.
Acute limb ischemia
The first autonomous pressure-guided system for limb protection
- Pressure measured
- Pressure controlled
- Limbs preserved
The Tulyp Mission
Our mission is to develop intelligent, pressure-controlled perfusion technologies that preserve tissue viability, improve clinical outcomes, and set a new standard of care for patients with compromised blood flow.
Acute Limb Ischemia
Acute Limb Ischemia (ALI) is a sudden loss of blood flow to a limb — a time-critical emergency where perfusion must be restored within hours to avoid tissue loss and amputation.
Low perfusion pressure
Hypotension and vasopressure dependence reduce the pressure that drives blood to the distal limb.
Thrombosis and embolism
Stagnant flow around the cannula and pre-existing clot occlude the smaller vessels downstream.
Vulnerable anatomy
Peripheral vascular disease and small-caliber arteries leave little reserve — common in small-body-habitus patients.
A Serious Clinical and Economic Burden
425,000+
Patients undergo high-risk femoral arterial procedures every year
2X
MORTALITYHigher in-hospital death with ALI
~8
DAYS LENGTH OF STAYAdded hospital days per ALI case
> $280K
CHARGESAdditional hospital charges per case
< 6
HOURSUntil loss of muscle occurs
Romero CM, Bashir R, et al. J Vasc Surg. 2023.
Kochar A, Kapur NK, et al. J Heart Lung Transplant. 2024.
An intelligent, purpose-built, perfusion platform
First-in-Human Results
Preclinical testing with the Tulyp System confirms the power of pressurized perfusion in a model of bilateral limb ischemia. Initiation of Tulyp after 6 hours of limb ischemia resulted in normalization of mean arterial pressure, microcirculatory flow, and tissue oxygenation compared to the contralateral limb without Tulyp. Additional preclinical studies have shown that active bypass with the Tulyp System provides superior limb perfusion compared to passive bypass (without the Tulyp System).
Translation of these mechanistic insights has begun with our first-in-human experience in 9 patients. Six patients undergoing cardiopulmonary support with occlusive femoral arterial cannulation received active bypass with the Tulyp System, demonstrating early safety with no device- or procedure-related adverse events through 24 hours, effective limb perfusion sustained for a median of ~2 hours (98% of support time), and ease of use. Three additional patients undergoing femoropopliteal bypass procedures further demonstrated the feasibility of the platform in a broader vascular surgery setting.
Tulyp Leadership
Multiple exits in cardiovascular medtech, deep domain experience in cardiogenic shock and MCS.
Peer-Reviewed Publications
The Distal Limb Perfusion Index (DLPI): A Novel Hemodynamic Parameter to Rapidly Identify Acute Limb Ischemia and Monitor…
View presentationIncidence and predictors of acute limb ischemia in acute myocardial infarction complicated by cardiogenic shock
Read articleAcute Distal Limb Ischemia After Large-Bore Arterial Access: An Expert Review and Consensus Recommendations
Read articlePrevention and Management of Acute Limb Ischemia when Using Temporary Mechanical Circulatory Support Devices
Read articleFactors associated with acute limb ischemia in cardiogenic shock and downstream clinical outcomes: Insights from…
Read articleTechnologies Targeting Acute Limb Ischemia in Cardiogenic Shock
View presentationLimb Ischemia in Patients with Peripheral Venoarterial Extracorporeal Membrane Oxygenation
View posterPressure-Controlled Perfusion
Read articleThe Tulyp System: A Novel Extracorporeal Pump that Provides Superior Limb Perfusion Compared to Passive Bypass in a Preclinical…
View presentationJoin us on the path to preventing ALI
The Tulyp Blood Pump is an investigational device currently under development and is not cleared or approved by the U.S. Food and Drug Administration (FDA) or any other global regulatory authority for commercial sale. This device is strictly limited by United States federal law to investigational use only. It is not available for purchase, clinical routine use, or prescription. The safety and effectiveness of The Tulyp Blood Pump have not yet been established. Any data, features, or intended uses described on this website represent ongoing research objectives and are subject to change based on clinical trial results and regulatory review.